Stay current with MiRXES


Media Releases

Keep up to date with our latest news and activities as we continue to innovate and develop our science and technology, bringing novel products to market. – from Singapore to the world.

Date: 23-11-2021

Yayasan MENDAKI and MiRXES , are pleased to announce today the setting up of the “MENDAKI – MIRXES Scholarship” for Malay/Muslim students who are pursuing undergraduate and post-graduate studies in Life and Biomedical Sciences. In addition to the scholarships, the students will also receive internship opportunities and securing employment opportunities with MiRXES upon their graduation.

Date: 06-10-2021

MiRXES announced today   the appointment of Mr. Cher Hwa TEO as Senior Vice President (SVP), Health Innovation Delivery and Chief of Staff. As the SVP of Health Innovation Delivery, Mr. Teo will help embed MiRXES into the Singapore healthcare ecosystem through downstream market access efforts by driving greater advocacy towards the adoption of MiRXES’s technology and products. 

Date: 06-10-2021

MiRXES announced today the appointment of Mr. Da LIU to its Board of Directors. Currently the Managing Director of CR-CP Life Science Fund, Mr. Liu leads investments in life sciences companies globally, especially those in emerging sectors such as RNA therapeutics and cancer screening.

Date: 06-10-2021

MiRXES announced today the appointment of Dr. David CAPES as Senior Vice President and Global Head of Innovation. In this newly created role, Dr. Capes will focus on the transformation of MIRXES from a regional SME to a global innovation enterprise over the next three years

Dr Holger Heyn

Date: 06-10-2021

Dr Holger Heyn, an expert in single-cell genomics and spatial transcriptomics, has joined the Scientific Advisory Board of MiRXES to help advance its development of RNA-powered multi-omics solutions for research and diagnostics


Date: 06-10-2021

This new capital will support MiRXES’s growth as a global leader in cancer early detection tests and preventive healthcare

Date: 06-10-2021

This study shows MiRXES qPCR profiling platform to be superior in reproducibility and detection rate compared to other commercial microRNA profiling platforms when used for validation of blood-based microRNA biomarkers.

Media Coverage

Stay informed and keep abreast with our media news.

20 Sep 2021

MiRXES, a Singapore biotechnology startup, has appointed Dr David Capes as its senior vice president and new global head of innovation on Sept 20.

8 Jul 2021

MiRXES has raised US$77 million in a Series C round, pushing  to commercialise its early cancer detection test kits globally. This latest round values the biotech at over US$500 million and could pave the way for a public listing.


Our partnerships

15 Sep 2021

代表取締役社長 橋爪 克仁 、 本社 山形県鶴岡市、以下「 HMT 」 と 、 MiRXES (ミレックサス Chief Executive Officer Zhou Lihan 、本社: シンガポール 、以下「 MiRXES 」 は、 マイクロ RNA 関連製品・サービスを日本において展開することに合意し、販売契約を締結しました 。

31 Aug 2021



Welcome to our knowledge base of insights in the frontiers of the biotech industry.

Across the many functional teams in MiRXES, from R&D to manufacturing and commercial, our women in science wear many different hats—to great success.

As the world’s first molecular blood test for detecting gastric cancer, GASTROClear could play a pivotal role in stopping the deadly disease in its earliest stages.

Media and Investor Contact

For media enquiries, please email:

Copyright © 2021 MiRXES Pte Ltd. All rights reserved. | Privacy Policy
Scroll to Top